$MDCX starting to wake up 👀 🔹 News flow picking up around SkinJect® and Teverelix® clinical programs 🔹 SkinJect® showed positive Phase 2 dose-response data,

$MDCX starting to wake up 👀 🔹 News flow picking up around SkinJect® and Teverelix® clinical programs 🔹 SkinJect® showed positive Phase 2 dose-response data, with the 200µg cohort emerging as the lead regimen 🔹 Company targeting non-melanoma skin cancer, Gorlin Syndrome, urology, oncology, and wo…